Latest News

Frontline acalabrutinib tablets have been approved by the FDA for the treatment of CLL and SLL.

Although AI can be effective in hematologic malignancies and palliative care, it must be used ethically, said Ram Prakash Thirugnanasambandam, MBBS.

AI-based models must be trained on data derived from diverse patient populations to eliminate potential bias in the context of palliative care.

Sunil W. Dutta, MD, discussed why clinical follow-up remains an essential soft skill for radiation oncologists in an increasingly automated field.

Charlotte Ivy Rivers, MD, discussed the importance of rare CNS tumor research, upcoming trial data in meningioma, and the role of functional radiosurgery.

Findings from the phase 1b/2 OrigAMI-4 trial support the regulatory decision for this regimen in this advanced head and neck cancer population.

Neoadjuvant mFOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma demonstrated a 100% R0 resection rate.

Experts discuss how issues related to prostate cancer diagnoses and access to care differ across practices based in the US and India.

Michael Wang, MD, discusses the impact of the MCL Scientific Consortium on the lymphoma community.

A phase 2 trial will determine whether subcutaneous blinatumomab can offer benefit to a patient population with no other treatment options.

The new living guideline contains updated recommendations for biomarker testing and therapeutic strategies based on factors such as PD-L1 expression status.

Fumiko Chino, MD, discussed the nuances of patient-centered care, addressing financial toxicity, AI bias in oncology, and survivorship.

Cytokines such as IL-17B, TNF-α, and IL-6 are essential in driving neuroendocrine differentiation and “reprogramming” healthy tissue.

A Prescription Drug User Fee Act date of December 18, 2026, has been set for tirabrutinib in this relapsed/refractory group.

The role of bispecific antibodies in mantle cell lymphoma treatment remains unclear, and they are not readily available in community sites, according to Tycel Phillips, MD.

Phase 2 CRDF-004 findings show that adding onvansertib to FOLFIRI and bevacizumab improves PFS in first-line RAS-mutated metastatic colorectal cancer.

Patient characteristics such as female sex and receipt of pylorus-preserving gastrectomy were protective of gallstone disease risk in those who had gastric cancer.

Researchers analyzed postoperative complications and survival outcomes in patients with melanoma who underwent therapeutic lymph node dissection.

Findings presented at the 2026 Tandem Meetings showed that an accelerated immune constitution of donor-derived CD4-positive T cells was observed with TRX103.

Data from the EXCALIBER-RRMM trial support the application for iberdomide plus standard therapy in this relapsed/refractory multiple myeloma population.

Encorafenib, cetuximab, and FOLFIRI improved PFS vs in treatment-naive BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER trial.

Monthly dosing of subcutaneous amivantamab may confer consistent outcomes with the previously approved biweekly dosing schedule in EGFR-mutant NSCLC.

According to Emese Zsiros, MD, PhD, FACOG, the pembrolizumab regimen yields favorable responses and survival in this PROC population.

Further follow-up is necessary to see if AZD0120 may be preferentially used as a treatment for patients with relapsed/refractory multiple myeloma.

Neoadjuvant therapy improves survival for patients with upfront resectable pancreatic cancer and minor PMV abutment vs an upfront surgical approach.

Emese Zsiros, MD, PhD, FACOG, spoke about the newly approved pembrolizumab regimen in PD-L1–expressing, pretreated platinum-resistant gynecologic cancers.

Experts convene at the 2025 MCL Scientific Consortium to spark collaborations, advance novel therapies, and boost patient outcomes through foundation-driven research support.

Pranshu Mohindra, MD, outlined considerations for optimizing the use of hypofractionated radiation for patients with lung cancer.

Although many clinical trials end due to strategic reasons, easing inclusion criteria and reducing potential operational failure may mitigate terminations.

J. Isabelle Choi, MD, discussed proton and photon therapy for locoregional recurrences, emphasizing advanced IMRT/VMAT techniques and CTV delineation.

Investigators will share detailed results from the phase 3 LIBRETTO-432 trial assessing selpercatinib in NSCLC at a future medical meeting.